Linking atrial fibrillation with non-alcoholic fatty liver disease: potential common therapeutic targets

被引：16

作者：

Ding, Ya-Hui ^{[1
,3
]}

Ma, Yuan ^{[1
,3
]}

Qian, Lin-Yan ^{[1
,3
]}

Xu, Qiang ^{[1
,3
]}

Wang, Li-Hong ^{[1
,3
]}

Huang, Dong-Sheng ^{[2
,3
]}

Zou, Hai ^{[1
,3
]}

机构：

[1] Zhejiang Prov Peoples Hosp, Dept Cardiol, Hangzhou 310014, Zhejiang, Peoples R China

[2] Zhejiang Prov Peoples Hosp, Dept Hepatobiliary Surg, Hangzhou 310014, Zhejiang, Peoples R China

[3] Hangzhou Med Coll, Peoples Hosp, Hangzhou 310014, Zhejiang, Peoples R China

来源：

ONCOTARGET | 2017年 / 8卷 / 36期

关键词：

non-alcoholic fatty liver disease; atrial fibrillation; adiponectin; insulin resistance; renin angiotensin aldosterone system; CORONARY-HEART-DISEASE; CIRCULATING ADIPONECTIN LEVELS; ANGIOTENSIN-CONVERTING ENZYME; MOLECULAR-WEIGHT ADIPONECTIN; INCREASED ENERGY-EXPENDITURE; INSULIN-RESISTANCE; METABOLIC SYNDROME; HEPATIC STEATOSIS; OXIDATIVE STRESS; DIABETES-MELLITUS;

D O I：

10.18632/oncotarget.19522

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Non-alcoholic fatty liver disease (NAFLD) and atrial fibrillation (AF) are common chronic non-infectious diseases with rising incidences. NAFLD is an independent risk factor for the onset of AF, after adjusting potentially related factors. The pathogenesis of these diseases share several mechanisms including reduced adiponectin level, insulin resistance, and renin angiotensin aldosterone system (RAAS) activation, in addition to activation of common disease pathways that promote inflammation, oxidative stress, and fibrosis. Furthermore, statins and RAAS blockers exert therapeutic effects concurrently on NAFLD and AF. The common pathogenesis of NAFLD and AF may serve as a potential therapeutic target in the future.

引用

页码：60673 / 60683

页数：11

共 50 条

[31] Present and future therapeutic strategies in non-alcoholic fatty liver disease
Calamita, Giuseppe
Portincasa, Piero
EXPERT OPINION ON THERAPEUTIC TARGETS, 2007, 11 (09) : 1231 - 1249
[32] Therapeutic potential of Medical Nutrition Therapy (MNT) in Non-Alcoholic Fatty Liver Disease (NAFLD)
Bawah, Abdul-Malik
Abdulai, Kasim
Amenya, Priscilla Cecilia Akpene
HUMAN NUTRITION & METABOLISM, 2025, 40
[33] Association between Atrial Fibrillation and Advanced Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease
Kang, Min Kyu
Park, Jung Gil
Kim, Min Cheol
YONSEI MEDICAL JOURNAL, 2020, 61 (10) : 860 - 867
[34] Current treatment of non-alcoholic fatty liver disease
Ahmed, Mohamed H.
Byrne, Christopher D.
DIABETES OBESITY & METABOLISM, 2009, 11 (03) : 188 - 195
[35] Future therapy for non-alcoholic fatty liver disease
Issa, Danny
Patel, Vaishali
Sanyal, Arun J.
LIVER INTERNATIONAL, 2018, 38 : 56 - 63
[36] Thyroid dysfunction and non-alcoholic fatty liver disease
Efstathiadou, Zoe A.
Kita, Marina D.
Polyzos, Stergios A.
MINERVA ENDOCRINOLOGICA, 2018, 43 (03) : 367 - 376
[37] Iron overload and non-alcoholic fatty liver disease
Datz, Christian
Mueller, Elena
Aigner, Elmar
MINERVA ENDOCRINOLOGICA, 2017, 42 (02) : 173 - 183
[38] Paediatric non-alcoholic fatty liver disease: an overview
AlKhater, S. A.
OBESITY REVIEWS, 2015, 16 (05) : 393 - 405
[39] HEPATOCELLULAR CARCINOMA AND NON-ALCOHOLIC FATTY LIVER DISEASE: A DANGEROUS LIAISON
Nevola, R.
Acierno, C.
Sasso, F. C.
Marrone, A.
Buffardi, F.
Adinolfi, L. E.
Rinaldi, L.
WORLD CANCER RESEARCH JOURNAL, 2019, 6
[40] Diabetes mellitus and non-alcoholic fatty liver disease: the thread of Ariadne
Kosmidou, Maria
Milionis, Haralampos
MINERVA ENDOCRINOLOGICA, 2017, 42 (02) : 109 - 121

← 1 2 3 4 5 →